Takeda announces discontinuation of the phase 3 clinical trial TOURMALINE-AL1 in AL amyloidosisAccess, AL amyloidosisJune 6, 2019
The European Medicines Agency (EMA) approves Melflufen (Pepaxti®) for the treatment of refractory myelomaAccess, MyelomaAugust 30, 2022
EMA CHMP gives positive opinion on isatuximab combination for newly diagnosed myeloma patientsAccess, latest, Myeloma, NewsNovember 20, 2024
MPE comments on the Implementing Regulation on joint scientific consultations on medicinal products for human use at Union levelAccess, latest, NewsOctober 29, 2024
The FDA approves belantamab mafodotin for relapsed or refractory myelomaAccess, MyelomaAugust 6, 2020
During European Myeloma Day, MPE highlights the importance of improving access to clinical trialsAccess, MPE, MyelomaSeptember 27, 2024
EMA recommends a new indication for daratumumab in adult patients with newly diagnosed myeloma who are eligible for autologous stem cell transplantAccess, MyelomaSeptember 26, 2024
Myeloma Patients Europe report finds huge inequalities in access to myeloma clinical trials in Central and Eastern EuropeAccess, MyelomaJune 25, 2023
A second bispecific antibody is approved as a fourth-line treatment for myeloma in England and WalesAccess, latest, Myeloma, NewsJuly 17, 2024
Q&A: US Food and Drug Administration (FDA) approves MRD as a basis for accelerated approval in myelomaAccess, MPE, MyelomaApril 18, 2024
